We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Regulator authorises treatment for sickle cell disease and beta thalassaemia
T-Therapeutics hopes to use genetically engineered rodents and machine learning to discover drugs
Covid may have abated, but emerging diseases and new drug categories are keeping the analytics firm busy
Wegovy found to have ‘quite profound’ effect on reducing risk of heart attacks, says pharma group
Anglo-Swedish drugmaker’s oncology and rare disease medication sales offset waning demand for Covid jabs
US and UK regulators say diabetes medication showed ‘significant’ weight loss benefits
German group is examining spinning off its crop sciences or consumer health businesses in effort to restore fortunes
Preliminary probe looks into financial communications around 2017 launch of group’s blockbuster drug Dupixent
German group slashes guidance by €1bn and reduces spending as it expects fewer first vaccine doses and lower boosting
Drugmakers claim that Brussels’ market exclusivity overhaul will reduce R&D investment
Biotech blames weaker US sales after lowering full-year forecast
Danish group has expanded manufacturing capacity but says demand will continue to outstrip supply
First jab for respiratory syncytial virus powers sales at UK drugmaker
Domestically made products like syringes currently cost more than those produced in China
Emerging research is challenging a widely held belief that new cases of the condition will rise exponentially as people live longer
UK Biobank’s records of 500,000 people promise breakthroughs in diseases and ageing
French pharma group announces consumer unit split and increased R&D investment
Pioneering medicines developed by Eisai and Eli Lilly shown to be more effective when taken earlier
Sector has been critical of government after sharp rise in clawback tax
Biotech acquisitions this year intended to cement position as market leaders in weight-loss field
It’s the super-science revolutionising skincare. And it might help protect the planet
Bolt-on acquisitions, however interesting, will not get Swiss pharmaceuticals group Roche out of its funk
Drugmaker upbeat on full data after initial findings disappointed investors
Swiss pharma group acquires rights to develop and manufacture bowel disease treatment
No, but it’s mildly interesting to ask
International Edition